Antipsychotic Polypharmacy in Clinical Practice

Guideline Positions and Clinical Reality

The American Psychiatric Association recommends antipsychotic monotherapy exclusively and does not acknowledge situations warranting antipsychotic polypharmacy (APP) 1, 2
NICE guidelines advise against regular combined antipsychotic use, except briefly during medication transitions 3, 1
The World Federation of Societies of Biological Psychiatry recommends APP only for treatment-resistant cases 1, 2
The Finnish Current Care Guideline acknowledges that some patients benefit from concurrent antipsychotics, particularly aripiprazole combinations for negative symptoms 1, 4
APP prevalence ranges from 16% in North America to 32% in Asia, with some studies reporting up to 57.5% of patients receiving APP for at least 90 days 1, 4

Insufficient response to monotherapy for positive symptoms (hallucinations, delusions) is a frequently cited reason for APP 3, 4, 5
Prescribers add second antipsychotics to reduce negative symptoms (social withdrawal, flat affect, lack of motivation), with aripiprazole augmentation showing specific benefit (standardized mean difference −0.41, 95% CI −0.79 to −0.03, p = 0.036) 4, 5, 6
NICE guidelines specifically permit adding another antipsychotic to augment clozapine when clozapine monotherapy proves ineffective 3, 1, 2
The combination of clozapine with another second-generation antipsychotic (possibly risperidone) may offer advantages over monotherapy 1, 2

The evidence supporting APP is problematic, with a 2021 meta-analysis finding antipsychotic augmentation superior to monotherapy for total symptom reduction, but this benefit appeared only in open-label low-quality trials, not in double-blinded or high-quality studies 4, 5, 6
Another meta-analysis of 42 antipsychotic combinations found no clear evidence recommending APP over monotherapy, with effect sizes inversely correlated with study quality 7, 4
APP is associated with increased global side effect burden, including higher rates of Parkinsonian effects, anticholinergic medication needs, hyperprolactinemia, sexual dysfunction, hypersalivation, sedation, cognitive impairment, and diabetes 4, 5, 6

Select antipsychotics with differing side-effect profiles to avoid compounding adverse effects 4, 5, 6
Start with lower doses of each medication to minimize side effects 4, 5, 6
Establish clear treatment goals and reassessment timelines 4, 5, 6
Monitor regularly for adverse effects, including metabolic parameters 4, 5, 6
Consider aripiprazole specifically for negative symptom reduction or metabolic side effect mitigation 4, 5, 6

Antipsychotic polypharmacy, including long-acting injectable (LAI) combinations, is widely used in practice, with rates ranging from 16% in North America to 32% in Asia, and correlates specifically with greater use of long-acting injectable formulations 8, 9

A Hungarian nationwide study found that combinations with depot formulations (excluding risperidone depot) were associated with less treatment discontinuation compared to oral polypharmacy 10
A Finnish nationwide cohort study (n=62,250) demonstrated that polytherapy combinations including long-acting injectables were among the ten most effective treatments, with individuals at 7-13% lower risk of psychiatric hospitalization when treated with antipsychotic polypharmacy versus monotherapy 10
Patients switching from clozapine or long-acting injectable polypharmacy combinations to monotherapy showed no differences in symptoms or side effects, suggesting these combinations can be maintained safely when clinically indicated 11

The use of dual LAI therapy increases the risk of extrapyramidal symptoms, such as Parkinsonian effects, and the need for anticholinergic medications 12
Dual LAI therapy also increases the risk of hyperprolactinemia, sexual dysfunction, and sedation 12
Consideration of drug-drug interactions and cytochrome P450 metabolic pathways is necessary when using dual LAI therapy 12

The American Academy of Child and Adolescent Psychiatry recommends against routine antipsychotic polypharmacy, except in specific circumstances, such as treatment of multiple distinct disorders, for example, a stimulant and an SSRI for ADHD and anxiety 13

Before adding any second antipsychotic, verify that the current antipsychotic is at therapeutic dose and has been trialed for adequate duration, and document failure of at least two adequate monotherapy trials with different antipsychotics 13
Assess whether lamotrigine 150mg is adequate for mood stabilization, with therapeutic range typically 100-400mg for bipolar disorder 14 15

If antipsychotic polypharmacy becomes necessary after optimizing monotherapy, select antipsychotics with differing side-effect profiles, start with lower doses, and establish clear treatment goals with specific symptom targets and reassessment timelines 13
Monitor regularly for extrapyramidal symptoms, metabolic parameters, and cardiovascular effects 13 16